Evidence map›Paper›PMID 37097894›Full record

ArticleRheumatology (Oxford, England)2024

Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.

Gurjit S Kaeley, Georg Schett, Philip G Conaghan, Dennis McGonagle, Frank Behrens, Philippe Goupille, Corine Gaillez, Bhumik Parikh, Catherine Bakewell

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02745080 (A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02745080 phase3completednot on this map

A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis

TypeinterventionalSponsorNovartis PharmaceuticalsRan2017 to 2019Enrolled853ConditionsPsoriatic ArthritisArmsSecukinumab, Adalimumab
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 5 countries.

Gurjit S KaeleyDivision of Rheumatology, University of Florida, Jacksonville, FL, USA.ORCID 0000-0003-1335-3131
Georg SchettDepartment of Internal Medicine 3: Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Philip G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Dennis McGonagleLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Frank BehrensRheumatology and Fraunhofer ITMP: Translational Medicine and Pharmacology and Fraunhofer Cluster of Excellence, Immune-Mediated Diseases, Goethe University, Frankfurt, Germany.
Philippe GoupilleUniversity Hospital of Tours, University of Tours, Tours, France.
Corine GaillezNovartis Pharma AG, Basel, Switzerland.
Bhumik ParikhAbbVie, Inc, North Chicago, IL, USA.
Catherine BakewellIntermountain Healthcare Medical Group, Salt Lake City, UT, USA.
University of Leeds · GBAbbVie (United States) · USGoethe University Frankfurt · DEIntermountain Healthcare · USNovartis (Switzerland) · CHUniversitätsklinikum Erlangen · DEUniversité de Tours · FRUniversity of Florida · US

Funding

East Hanover, NJNovartis Pharmaceuticals Corporation
6 · The paper itself

Abstract

objectivesTo evaluate enthesitis treatment response, including time to resolution and data from multiple enthesitis instruments, in patients with PsA treated with secukinumab or adalimumab for 52 weeks.

methodsIn this post hoc analysis of the EXCEED study, patients receiving secukinumab 300 mg or adalimumab 40 mg per the label were grouped by presence or absence of baseline enthesitis based on the Leeds Enthesitis Index (LEI) and the Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC). Efficacy was assessed according to several enthesitis-related instruments using non-responder imputation for the achievement of enthesitis resolution (LEI/SPARCC = 0), Kaplan-Meier analysis for time to resolution, and as-observed data for other outcomes.

resultsEnthesitis was present at baseline in 498 of 851 patients (58.5%) as assessed by LEI and in 632 of 853 patients (74.1%) as assessed by SPARCC. Patients with baseline enthesitis generally presented with greater disease activity. Similar proportions of patients receiving secukinumab or adalimumab achieved resolution of LEI and SPARCC at weeks 24 (secukinumab: LEI/SPARCC, 49.6%/45.8%; adalimumab: LEI/SPARCC, 43.6%/43.5%) and 52 (secukinumab: LEI/SPARCC, 60.7%/53.2%; adalimumab: LEI/SPARCC, 55.3%/51.4%), with comparable mean time to enthesitis resolution. Improvements were similar for both drugs at individual enthesitis sites. Resolution of enthesitis with secukinumab or adalimumab was associated with improvements in quality of life at week 52.

conclusionSecukinumab and adalimumab showed similar efficacy, including time to resolution, with respect to resolution of enthesitis. Inhibition of IL-17 with secukinumab reduced clinical enthesitis similarly to TNF-α inhibition.

trial registrationClinicalTrials.gov, NCT02745080.

Indexed as

Antirheumatic AgentsArthritis, PsoriaticEnthesopathySpondylarthritisAdalimumabAntibodies, Monoclonal, HumanizedHumansQuality of LifeTreatment OutcomeAdalimumabAntibodies, Monoclonal, HumanizedAntirheumatic AgentssecukinumabbDMARDsbiologicsenthesitishead-to-headIL-17 inhibitorPsAsecukinumab

Identifiers

PMID37097894
PMCPMC10765155
OpenAlexW4366996849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.